Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2020

Stockholders' Equity Note [Abstract]

Share-based Compensation, Stock Options, Activity

A summary of employees’ stock options activities during the nine months ended September 30, 2020 is as follows:

	Nine Months Ended September 30, 2020 (unaudited)
	Number	Weighted average exercise price		Aggregate intrinsic value (in thousands)		Weighted average remaining contractual life (years)
Options outstanding as of January 1, 2020	454,348	$	20.628	$	25,935	4.343
Granted	—	$	—
Exercised	(121,487)	$	20.177
Forfeited and expired	(500)	$	1.576
Options outstanding and exercisable as of September 30, 2020	332,361	$	20.822	$	31,441	3.673

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range

The options outstanding as of September 30, 2020 (unaudited) have been separated into ranges of exercise price as follows:

Range of exercise price				Options outstanding and exercisable as of September 30, 2020	Weighted average remaining contractual life (years)	Weighted average exercise price of options outstanding and exercisable
$	6.230	—	8.800	10,356	1.356	$	8.289
$	12.470	—	16.870	89,825	3.371	$	14.282
$	19.510	—	24.230	173,998	3.786	$	21.440
		$29.880		46,588	4.395	$	29.880
		$39.860		11,594	3.474	$	39.860
				332,361	3.673	$	20.822

Schedule of Stockholders' Equity Note, Warrants or Rights

The Company’s outstanding options granted to consultants for services as of September 30, 2020 (unaudited) were as follows:

	Options outstanding and exercisable as of September 30, 2020	Exercise price per share		Exercisable through
	(number)
August 2013	3,100	$	21.140	August 2023
March 2014	2,300	$	39.860	March 2024
May 2014	2,600	$	22.010	May 2024
November 2014	4,038	$	21.660	November 2024
February 2016	1,000	$	16.870	February 2026
	13,038

Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity

A summary of restricted stock units and performance stock units for employees, consultants and non-employee directors of the Company for the nine months ended September 30, 2020 (unaudited) is as follows:

	Number of shares underlying outstanding restricted stock units	Weighted- average grant date fair value
Unvested balance - January 1, 2020	2,559,083	$	49.58
Granted	1,361,881	$	86.27
Vested	(898,820)	$	44.28
Forfeited	(156,613)	$	60.23
Unvested balance – September 30, 2020	2,865,531	$	68.10

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs

The Company recognized non-cash stock-based compensation expense in the consolidated statements of operations as follows:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2020		2019		2020		2019
	(unaudited) (in thousands)				(unaudited) (in thousands)
Cost of revenues	$	1,476	$	637	$	3,615	$	1,967
Research and development	6,000		3,476		15,767		9,674
Sales and marketing	7,184		3,932		18,773		11,015
General and administrative	4,018		2,977		11,029		12,123
Total	$	18,678	$	11,022	$	49,184	$	34,779